SCHEMBL1715950

SCHEMBL1715950

NOC(CS(=O)(=O)c1ccccc1)c1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 5/20 0.45
PSIP1 O75475 1/20 0.44
CYP1A2 P05177 1/20 0.40
GAA P10253 1/20 0.40
CYP2C19 P33261 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
GBA1 P04062 1/20 0.40
ALDH1A1 P00352 2/20 0.38
CA12 O43570 2/20 0.38
CA1 P00915 2/20 0.38
CA2 P00918 2/20 0.38
CA7 P43166 2/20 0.38
CA9 Q16790 2/20 0.38
IDO1 P14902 1/20 0.38
TDO2 P48775 1/20 0.38
CA3 P07451 1/20 0.38
CA4 P22748 1/20 0.38
CA6 P23280 1/20 0.38
CA5A P35218 1/20 0.38
PLA2G7 Q13093 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24506357 0.80 HSD11B1 (0.47) HSD11B1CYP1A2
SCHEMBL11858188 0.79 PSIP1 (0.46) HSD11B1PSIP1CYP1A2GAACYP2C19
SCHEMBL24503498 0.77 PABPC1 (0.48) HSD11B1PSIP1CYP1A2GAACYP2C19
SCHEMBL26511389 0.76 HSD11B1 (0.49) HSD11B1PSIP1CYP1A2GAACYP2C19
SCHEMBL28956494 0.76 GBA1 (0.56) HSD11B1PSIP1GBA1ALDH1A1CA12
SCHEMBL24333911 0.74 HSD11B1 (0.45) HSD11B1PSIP1CYP1A2GAACYP2C19
SCHEMBL28748984 0.72 HSD11B1 (0.71) HSD11B1PSIP1CYP1A2GAACYP2C19
SCHEMBL12237251 0.72 HSD11B1 (0.71) HSD11B1PSIP1CYP1A2GAACYP2C19
SCHEMBL28397073 0.72 HSD11B1 (0.71) HSD11B1PSIP1CYP1A2GAACYP2C19
SCHEMBL17018545 0.72 PSIP1 (0.54) HSD11B1PSIP1GBA1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070244117-A1 Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof LEO PHARMA A/S (DK) 2007-10-18 US claimed
US-8034811-B2 Hydroxamic acid esters and pharmaceutical use thereof LEO PHARMA A/S (DK) 2011-10-11 US disclosed
EP-1697312-B1 HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF LEO PHARMA AS (DK) 2011-07-20 EP disclosed
US-20070244117-A1 Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof LEO PHARMA A/S (DK) 2007-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070244117-A1 Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof F9, F12, HDAC9 HSD11B1 577/4885PSIP1 4545/4885CYP1A2 2984/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.